Nikkei 225
Shionogi &
A Japanese pharmaceutical company developing treatments for infectious and central-nervous-system diseases. Nikkei 225 constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
4507.T Updated Jul 11, 2026 2 AI consumers
Annual return · 2026-07-10'21+15%'22-2.2%'23+17.8%'24-1%'25+42.4%YTD-9.8%
Money in ▸·
Shionogi &~¥440B
▸ Money out·
Financials & Segments
- Total revenue · ~¥440B (FY2024)
- Segments · Pharmaceuticals
Revenue from
No refined links yet.
Pays to
No refined links yet.